**12. Emergency treatment if cyanotic CHD is suspected**

If a cyanotic CHD is suspected, PGE1 should be started or made available. The starting dose is 0.05 to 0.1 µg/kg/min, administered in a continuous IV drip. When the desired effects

Evaluation and Emergency Treatment of

2007;357:1928-38.

Criticlly Ill Neonate with Cyanosis and Respiratory Distress 251

[9] Newburger JW, Jonas RA, Wernovsky G. A comparison of the preoperative neurologic

[10] Miller SP, McQuillen PS, Hamrick S, Xu D, Glidden DV, Charlton N. Abnormal brain

[11] Tabbutt S, Nord AS, Jarvik GP. Neurodevelopmental outcomes after staged palliation

[12] Dorfman AT, Marino BS, Wernovsky G, Tabbutt S, Ravishankar C, Godinez RI, et al.

[13] Behrman RE, Kliegman RM, Jenson HB. Nelson Textbook of Pediatrics (17th edition).

[14] Senka Mesihović- Dinarević. Dječija kardiologija: od fetusa do adolescenta. Medicinski

[15] Gomella TL. Neonatology: Management, Procedures, On-Call Problems. Diseases, and

[16] Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al.

[18] Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. *Semin Perinatol*. Feb

[19] Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on

[20] UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation.

[21] Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. *Cochrane* 

[22] Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al.

[24] Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, et al. A

[25] Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. *J Perinatol*. Dec 2008;28 Suppl 3:S67-71. [Medline]. [Full Text].

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med*. Feb 9 2006;354(6):579-87. [Medline]. [17] Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, et al. Intravenous

sildenafil in the treatment of neonates with persistent pulmonary hypertension. *J* 

UK Collaborative ECMO Trail Group. *Lancet*. Jul 13 1996;348(9020):75-

Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. *Pediatrics*. Jan 2000;105(1 Pt 1):14-20. [Medline]. [23] Wung JT, James LS, Kilchevsky E, James E. Management of infants with severe

respiratory failure and persistence of the fetal circulation, without

randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. *Pediatrics*. Mar

for hypoplastic left heart syndrome. Pediatrics 2008;121:476-83.

in infant heart surgery. N Engl J Med 1993;329:1057-64.

center. Pediatr Crit Care Med 2008;9:193-202

Drugs (4th edition). Appleton & Lange; 1999

*Pediatr*. Dec 2009;155(6):841-847.e1. [Medline].

PPHN. *Semin Perinatol*. Feb 2005;29(1):8-14.[Medline].

*Database Syst Rev*. Aug 10 2011;CD005494.[Medline].

hyperventilation. *Pediatrics*. Oct 1985;76(4):488-94. [Medline].

Philadelphia: W.B.Sauders, 2004

fakultet ,Sarajevo; 2000

2005;29(1):15-23. [Medline].

2004;113(3 Pt 1):559-64.[Medline].

82. [Medline].

effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass

development in newborns with congenital heart disease. N Engl J Med.

Critical heart disease in the neonate: Presentation and outcome at a tertiary care

(increased Po2, increased systemic blood pressure, and improved pH) are achieved, the dose should be reduced step-by-step to 0.01µg/kg/min. When there is no effect with the initial starting dose, it may be increased to 0.4 µg/kg/min.

If echocardiography is not immediately available, the clinician caring for a newborn with possible cyanotic heart disease should not hesitate to start a prostaglandin infusion ( for a possible ductal-dependent lesion). Because of the risk of hypoventilation associated with prostaglandins, a practitioner skilled in neonatal endotracheal intubation must be available. Three common side effects of Prostaglandin E1 IV infusion are apnea (12%), fever (14%), and flushing (10%).
